Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials

  ()
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia. read more >

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference

Research Report
  ()
Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. read more >

Gold at Year-End and a Lesson in Shorting

Contributed Opinion
  ()
Ron Struthers of Struthers' Resource Stock Report provides his outlook on gold stock performance going into the end of the year, offers a lesson in Shorting 101, and discusses his views on particular companies. read more >

Cannabis Company Forms Partnership to Develop Pharmaceuticals

Research Report
  ()
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. read more >

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market

  ()
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. read more >
Management Q&A: View from the Top

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

Managment Q&A: View from the Top
  ()
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi. read more >

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia

  ()
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts. read more >
Expert Investing Ideas

"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research


Register For New Orleans 2017

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Japan Is Fertile Ground for Biotech Deals

  ()
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. read more >

Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'

Research Report
  ()
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. read more >

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

Research Report
  ()
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. read more >

Gout, Kidney Stones, Liver Disease & Cannabinoids

Contributed Opinion
  ()
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. read more >
Register For New Orleans 2017